Retatrutide GLP-3
Your Weight Loss Weapon

Retatrutide: The Next Step in Weight-Loss Medicine

Retatrutide is the most powerful weight-loss compound to come out of the GLP-1 era so far. It's a once-a-week injection that works on three different hormone systems at the same time. In large clinical trials, it has produced weight loss that comes close to what people usually see only after bariatric (weight-loss) surgery.

Retatrutide is an investigational drug, which means it's still being studied and isn't approved for sale yet. It's also "first-in-class," meaning nothing else quite like it has come before. It works by switching on three hormone receptors that help control metabolism: GLP-1, GIP, and glucagon. Because it activates all three, people often call it a "triple agonist" or "triple G." It's being developed by Eli Lilly and is given as a once-weekly shot under the skin.

Based on widely cited projections from industry trackers, Eli Lilly is expected to file its New Drug Application (the formal request for FDA approval) in late 2026. Approval could follow in 2027, though it may slip to 2028. These timelines assume the remaining trials finish on schedule and the FDA's review goes smoothly. It's worth noting these are estimates, not dates confirmed by Eli Lilly.

How Retatrutide Compares

Retatrutide belongs to the same broad family as today's well-known weight-loss and diabetes drugs, but it goes a step further in how it works:

• Semaglutide (sold as Wegovy or Ozempic) targets one receptor: GLP-1.

• Tirzepatide (sold as Zepbound or Mounjaro) targets two: GLP-1 and GIP.

• Retatrutide targets all three, adding glucagon-receptor activity. This extra target is thought to help the body burn more energy, on top of reducing appetite.

How It Works

Each of the three receptors plays its own role:

• GLP-1 receptor: Slows down how fast the stomach empties, increases the feeling of being full, and reduces appetite. This is the main mechanism shared across this whole class of drugs.

• GIP receptor: Another gut-hormone pathway that works alongside GLP-1 to help regulate blood sugar and appetite. This is the added effect behind tirzepatide.

• Glucagon receptor: The third and most distinctive target. Activating it is thought to raise the body's energy use and affect how the liver handles fat, which may add to weight loss beyond appetite control alone.

One more notable point: retatrutide's body-composition data (mostly from Phase 2 DXA scans, which measure fat versus lean mass) showed that roughly 62–69% of the weight people lost came from fat.